This project

is developed

by TIRF Labs

www.TIRF-Labs.com

T: 919.463.9545

i-Diagnostics®
The Handheld Future of Precision Medicine

Copyright © 2021, TIRF Labs, Inc. All photographic images, schemes and text located at this web site are protected by US copyright laws and international treaties.

To use them, please contact TIRF Labs at: info@TIRF-Labs.com. Include a description of the purpose and location for placement.  

Terms and ConditionsPrivacy PolicyLiterature Cited FDA Compliance Blog Copyright Credits

i-diagnostics@TIRF-Labs.com

i-Diagnostics Blog


This blog invites you to share your opinions and ideas on emerging and propagating pandemics. The COVID-19 crisis demonstrated that we need a global infrastructure, which would help to prevent, localize and combat pandemics. Scientific and technological capabilities for efficient management of pandemics already exist. Scientists and medical professionals have outlined the necessary measures on COVID-19 in the Great Barrington Declaration and in the Open Letter of Belgian Medical Doctors. The development of new vaccines, even if the pathogen does not mutate, in principle, cannot be fast. Therefore, re-purposing of previosly approved drugs (approved for other purposes) to combat new pathogens appears to be a productive approach.



Ivermectin


In particular, in the case of of COVID-19, Ivermectin is proving to be a global solution to the current pandemic of corona virus. Ivermectin is FDA-approved as an antiparasitic agent. It was discovered in 1975 and came into medical use in 1981.  In 2015 Nobel Prize for Physiology or Medicine was awarded for the discovery of ivermectin. It is on the World Health Organization's List of Essential Medicines. Ivermectin is currently under numerous clinical trials for prophylaxis and treatment of COVID-19 [https://clinicaltrials.gov/]. In recently published “Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19” Dr. Pierre Kory,  et alter wrote: “In March 2020, an expert panel called the Front Line COVID-19 Critical Care Alliance (FLCCC) was created and led by Professor Paul E. Marik with the goal of continuously reviewing the rapidly emerging basic science, translational, and clinical data in order to gain insight into and develop a treatment protocol for, COVID-19. At the same time, many centers and groups employed a multitude of novel therapeutic agents empirically and within clinical trials, often during inappropriate time points during this now well-described multi-phase disease. Either as a result of these frequent trial design failures or due to the lack of sufficient anti-viral or anti-inflammatory properties, nearly all trialed agents have proven ineffective in reducing the mortality of COVID-19. Based on a recent series of negative published therapeutic trial results, in particular the SOLIDARITY trial, this virtually eliminates any treatment role for remdesivir, hydroxychloroquine, lopinavir/ritonavir, interferon, convalescent plasma, tocilizumab, and mono-clonal antibody therapy. [Advances] Despite the growing list of failed therapeutics in COVID-19, the FLCCC recently discovered that ivermectin, an anti-parasitic medicine, has highly potent real-world, anti-viral, and anti-inflammatory properties against SARS-CoV-2 and COVID-19. This conclusion is based on the increasing study results reporting effectiveness, not only within in-vitro and animal models, but also in numerous clinical trials from centers and countries around the world. Repeated, consistent, large magnitude improvements in clinical outcomes have now been reported when ivermectin is used not only as a prophylactic agent but also in mild, moderate, and even severe disease states from multiple, large, randomized and observational controlled trials. Further, data showing impacts on population wide health outcomes have resulted from multiple large “natural experiments” that appear to have occurred when various regional health ministries and governmental authorities within South American countries initiated “ivermectin distribution” campaigns to their citizen populations in the hopes the drug would prove effective. The tight, reproducible, temporally associated decreases in case counts and case fatality rates in each of those regions compared to nearby regions without such campaigns, suggest that ivermectin is proving to be a global solution to the pandemic. This is now further evidenced by the recent incorporation of ivermectin as a prophylaxis and treatment agent for COVID-19 in the national treatment guidelines of Egypt as well as the state of Uttar Pradesh in Northern India, populated by 210 million people.”

Nasal spray of 1% ivermectin solution in glycerol formal

Nose and throat are the main gates for entering corona virus and other respiratory infections into human body.  It has been shown that nasal spray of 1% ivermectin serves as an efficient prophylaxis for COVID-19. Common side effects include burning nose when used for nasal spraying. Mouth sprays are better tolerated and are almost equally efficient. It is unclear if it is safe for use during pregnancy, but is probably acceptable for use during breastfeeding [https://clinicaltrials.gov/].

Email us

What do you think about the current pandemic?  What can we do now to prevent devastating pandemics in the future?

Do you think that availability of precise and accurate diagnostics for home use, similar to i-diagnostics, is critical for the current and future efforts?


We would be delighted to hear from you.

Links to Dr. Steven Hotze website:


https://www.hotzehwc.com/



Video with Transcript:

https://www.hotzehwc.com/2021/02/dr-hotze-on-the-dangers-of-the-covid-19-vaccine/


Dr. Hotze Article:  The So-Called COVID-19 “Vaccine” Is Really A Dangerous Experimental Gene Therapy – Just Say “No!”

https://www.hotzehwc.com/wp-content/uploads/2015/02/Covid-vaccine-flyer-corrected.pdf


Copy of Dr. Hotze’s Healthy Living Newsletter with article about COVID Vaccine

https://www.hotzehwc.com/wp-content/uploads/2015/02/Hotze-Healthy-Living-Newsletter-Feb-March-2021-1.pdf